Usage: Comes in powdered form and must be reconstituted with Bacteriostatic Water before administration in research uses.

Mechanism: It acts as a triple receptor agonist (GLP-1, GIP, and glucagon), supporting insulin release, promoting satiety, and influencing energy expenditure to aid in controlling metabolic function.

Storage: Keep refrigerated after reconstitution to maintain stability.

Shelf Life: Best used within four weeks once reconstituted.

Packaging: Each 3mL vial contains 5 mg of lyophilized powder for research purposes only.

Rodent Weight Reduction
Retatrutide was examined in a high-fat diet mouse model to evaluate body weight control. Over several weeks, researchers observed notable weight decreases and improved glucose tolerance. The effect was linked to diminished appetite and better metabolic balance, suggesting its utility in obesity-related studies.

Rat Insulin Sensitivity
Obese rats received retatrutide, resulting in enhanced insulin sensitivity and regulated blood glucose. Reduced food intake and lower body fat were also reported. This trial underscores retatrutide’s potential in alleviating metabolic complications linked to insulin resistance.

Primate Metabolic Assessment
Retatrutide was administered to non-human primates to assess long-term weight management and glycemic stability. Consistent decreases in body weight were recorded, alongside steady glucose control.

Retatrutide is a triple hormone receptor agonist with activity at GLP-1, GIP, and glucagon receptors. By enhancing insulin secretion, reducing appetite, and potentially boosting energy expenditure, it helps regulate body weight and glucose metabolism. Its combined action stimulates satiety signals, suppresses food intake, and aids in controlling blood sugar. This multi-faceted approach holds promise for treating obesity and related metabolic disorders, potentially including improvements in lipid metabolism.